Source access required
CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.
GP
Gefjon Pharma ApS
aktivCVR 44512971AnpartsselskabOle Maaløes Vej 3, 2200 København NForskning og eksperimentel udvikling inden for naturvidenskab og teknik
- Latest accounts
- 2026
- Statement scope
- Standalone
- Verified
- 05 Nov 2026
- Sources
- 5
What changed?
Source-backed changes, not an assessment.
1 source
Key figures
Latest period: 2026
Revenue
Data quality concern—
Data quality concern
Operating profit
DKK -4.4m
Latest period
Source details
Source: dk-regnskabsdata-live-44512971-1793879506880
Document: dk-regnskabsdata-44512971-AaAAYUss_jnrF2BJ0FkH-1
XBRL: fsa:ProfitLossFromOrdinaryOperatingActivities
Period: 01 Apr 2025 - 31 Mar 2026
Technical details
Context: D0
Unit: U-iso4217-DKK
Net result
DKK -4.2m
Latest period
Source details
Source: dk-regnskabsdata-live-44512971-1793879506880
Document: dk-regnskabsdata-44512971-AaAAYUss_jnrF2BJ0FkH-1
XBRL: fsa:ProfitLoss
Period: 01 Apr 2025 - 31 Mar 2026
Technical details
Context: D0
Unit: U-iso4217-DKK
Equity
DKK -5m
Equity ratio: -63.5%
Source details
Source: dk-regnskabsdata-live-44512971-1793879506880
Document: dk-regnskabsdata-44512971-AaAAYUss_jnrF2BJ0FkH-1
XBRL: fsa:Equity
Period: 01 Apr 2025 - 31 Mar 2026
Technical details
Context: I0
Unit: U-iso4217-DKK
Development
Reported values. Missing periods appear as gaps.
RevenueNet result
Tabular view of development
| Year | Revenue | Net result |
|---|---|---|
| 2023 | — | — |
| 2025 | — | DKK -195.5k |
| 2026 | — | DKK -4.2m |